ArticleScientific reports2016
Intranasal Administration of Chitosan Against Influenza A (H7N9) Virus Infection in a Mouse Model.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 64 citations in OpenAlex.
- Leveraging virucidal potential of an anti-microbial coating agent to mitigate fomite transmission of respiratory viruses.Current research in microbial sciences · 2024Article
- Physicochemical Properties and Antiherpetic Activity of κ-Carrageenan Complex with Chitosan.Marine drugs · 2023Article
- Anti-COVID-19 Credentials of Chitosan Composites and Derivatives: Future Scope?Antibiotics (Basel, Switzerland) · 2023Review
- Effect of chitooligosaccharide on the inhibition of SARS-CoV-2 main protease.Biomaterials research · 2023Article
- In Vitro Anti-HIV-1 Activity of Chitosan OligomersBiotech (Basel (Switzerland)) · 2023Article
- Article
- Antiviral functionalization of cellulose using tannic acid and tannin-rich extracts.Frontiers in microbiology · 2023Article
- Elucidating the antiviral potential of polysaccharides.EXCLI journal · 2023Article
- Low molecular weight chitooligosaccharide inhibits infection of SARS-CoV-2 in vitro.Journal of applied microbiology · 2022Article
- A review of the antiviral activity of Chitosan, including patented applications and its potential use against COVID-19.Journal of applied microbiology · 2022Review
- Development and Characterization of Antimicrobial Textiles from Chitosan-Based Compounds: Possible Biomaterials Against SARS-CoV-2 Viruses.Journal of inorganic and organometallic polymers and materials · 2022Article
- The Expanded Role of Chitosan in Localized Antimicrobial Therapy.Marine drugs · 2021Review
- SARS-CoV-2 inhibition using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray.Scientific reports · 2021Article
- Ag-Based Synergistic Antimicrobial Composites. A Critical Review.Nanomaterials (Basel, Switzerland) · 2021Review
- Preparation and Antimicrobial Activity of Chitosan and Its Derivatives: A Concise Review.Molecules (Basel, Switzerland) · 2021Review
- Underscoring the immense potential of chitosan in fighting a wide spectrum of viruses: A plausible molecule against SARS-CoV-2?International journal of biological macromolecules · 2021Review
- Chitosan-Based Nanoparticles Against Viral Infections.Frontiers in cellular and infection microbiology · 2021Review
- Review
- New Opportunity to Formulate Intranasal Vaccines and Drug Delivery Systems Based on Chitosan.International journal of molecular sciences · 2020Review
- Use of PELC/CpG Adjuvant for Intranasal Immunization with Recombinant Hemagglutinin to Develop H7N9 Mucosal Vaccine.Vaccines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza virus evolves constantly in an unpredictable fashion, making it necessary to vaccinate people annually for effective prevention and control of influenza. In general, however, during the first wave of an influenza outbreak caused by a newly emerging virus strain, influenza morbidity and mortality have been observed to rise sharply due to the lack of a matching vaccine. This necessitates the exploration of novel intervention approaches, particularly those prophylactic or therapeutic agents that have a broad range of antiviral activities and are also proven to be non-toxic. Here, we reported that stimulation of the innate immune system by intranasal administration of chitosan as a single agent was sufficient to completely protect BALB/c mice from lethal infection by H7N9 virus, a newly emerged viral strain that is highly pathogenic to humans. Remarkably, animals could still be protected against lethal challenge by H7N9 (10×LD50), even ten days after the intranasal chitosan administration. The significantly enhanced infiltration of leukocytes in the bronchoalveolar lavage and elevated levels of proinflammatory cytokines in the bronchia/lung tissues revealed the potent activation of mucosal immune responses by intranasally delivered chitosan. We also observed that chitosan can protect mice from three other virus strains. The marked breadth and magnitude of protection against diverse viral strains makes chitosan an attractive candidate as a universal anti-influenza agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.